shr0410
Small moleculeexperimental
Clinical trial activity
8 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
4
Phase 3
2
Phase 4
0
Earliest trial started Apr 15, 2018 (NCT03493191)
Timeline
Indications
Mechanism of action
- Kappa opioid receptorAGONIST
OPRK1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05394402 | Phase 2 | Aug 9, 2022 | Hengrui Therapeutics, Inc. |
| NCT05470049 | Phase 2 | Aug 1, 2022 | Hengrui Therapeutics, Inc. |
| NCT05459220 | Phase 3 | Jul 31, 2022 | Hengrui Therapeutics, Inc. |
| NCT04852003 | Phase 3 | May 31, 2021 | Hengrui Therapeutics, Inc. |
| NCT04317209 | Phase 1 | Apr 30, 2020 | Hengrui Therapeutics, Inc. |
| NCT04099927 | Phase 1 | Jul 28, 2019 | Hengrui Therapeutics, Inc. |
| NCT03857568 | Phase 1 | Mar 31, 2019 | Atridia Pty Ltd., Linear Clinical Research |
| NCT03493191 | Phase 1 | Apr 15, 2018 | Atridia Pty Ltd., Linear Clinical Research |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Hengrui Therapeutics, Inc. | For profit | 6 | 6 | 3 | 2019 |
| Atridia Pty Ltd. | For profit | 2 | 2 | 1 | 2018 |
| Linear Clinical Research | For profit | 2 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1